Regulatory considerations and commercialization of 3D printed MN mediate vaccine delivery

Abstract

3D printing or additive manufacturing is a process first introduced at 1980s. Since then, it showed great achievements in fabricating complex structures with ease in sectors such as industry as well as medical and pharmaceutical sectors. Creation of complex structures such as scaffolds, patient specific implants and MNs are few example of 3D printing in medical and pharmaceutical sector. Although the setup of 3D printer and workstation is costly, novel techniques and development of novel biomaterials are showing promising future of 3D printing in pharmaceutical sectors. Over the past decade, the benefits of a MNs in TDD and several applications and benefits of MN were found out. In this review article, commercialization of 3D printing MNs were brought into lime light along with the probable cost, regulatory affairs and consequences of mass production of 3D printed microneedle.